Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil for excessive sleepiness in mild or moderate TBI
NCT00893789Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Apr 2009
- Primary completion
- Jan 2011
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of armodafinil in Hypersomnia (HS) (4 arms), sponsored by Cephalon, Inc. Primary endpoints: Multiple Sleep Latency Test at 12 weeks and Clinical Global Impression of Change at 12 weeks. Started Apr 2009; status: terminated.
02
Drugs
armodafinil
03
Conditions
Hypersomnia (HS)
Beyond the preview
Go deeper on NCT00893789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00893789.